Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone Acetonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CNR1 | P21554 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone Acetonide SCHEMBL4448 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL16393966 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL4002585 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL12323208 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL5484214 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL13234864 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL13839748 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL11332717 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL21051778 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR | |
| Triamcinolone Acetonide SCHEMBL11911289 | 1.00 | HIF1A (1.00) | HIF1ACYP3A4LMNANR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177574-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200131265-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-10584181-B2 | Methods of making and using multispecific antibody panels and antibody analog panels | GENENTECH, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190218288-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2019-07-18 | — | — | US | disclosed |
| US-10100116-B2 | FcγRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| EP-2029173-B1 | FC RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-1534335-B9 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150344574-A1 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344575-A1 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9084799-B2 | Inhaled combination therapy | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-20060013810-A1 | Humanized FcgammaRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115452-A2 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050260213-A1 | Fcgamma-RIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005110474-A2 | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050215767-A1 | Fcgamma riib specific antibodies and methods of use thereof | MACROGENICS INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1534335-A2 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005018669-A1 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040185045-A1 | FcgammaRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004016750-A2 | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-4920180-A | Hydrophilic polymer | MENICON CO., LTD. (JP) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584181-B2 | Methods of making and using multispecific antibody panels and antibody analog panels | FCGR2A, FCGR3B, FCGR1A | NR3C1 1811/4885HIF1A 4674/4885CYP3A4 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.